People buy fish oil in part to help preserve their memory. In the two-year PreventE4 trial, researchers from the University of Southern California examined what happens after taking DHA, one of the omega-3 fatty acids. DHA levels in cerebrospinal fluid increased, but no benefits for memory or hippocampal volume preservation were found compared with placebo.
The claim that “omega-3 reached the brain” needs some qualification here: the researchers studied the fluid surrounding the brain and spinal cord, not DHA levels directly inside neurons. Even so, the findings are interesting precisely because of the combination of two observations: a biochemical change occurred, but the expected cognitive benefit did not emerge over two years.
The PreventE4 results were published on June 18, 2026. The trial included 365 people aged 55 to 80. They had normal cognitive function but at least one risk factor for dementia. Participants also consumed less than 200 mg of DHA per day through their diet.
DHA, or docosahexaenoic acid, is part of cell membranes, including those of neurons. This provides a biological basis for studying its role in brain function. But the presence of a substance in nervous tissue does not, by itself, confirm that taking more of it improves memory.
Participants were randomly assigned to one of two groups: one received DHA, and the other received a placebo. Neither the participants nor the researchers assessing the results knew who was in which group. Both groups also took a B-vitamin complex, so DHA was compared with placebo against the same background.
This was a phase IIa trial conducted at a single center. Its main purpose was to test the supplement’s biological effects: the primary endpoint was a change in the ratio of DHA to arachidonic acid in cerebrospinal fluid after six months. Memory and other cognitive functions were assessed as exploratory outcomes.
The supplement had an effect on the biochemical measure: the ratio of DHA to arachidonic acid in cerebrospinal fluid increased. This indicates a change in DHA availability in the central nervous system.
However, over two years, the DHA group showed no measurable advantage on memory tests. The difference between the groups in changes to the overall RBANS cognitive score was just 0.09 points. This result does not demonstrate that the supplement improved cognitive function.
No advantage was found in preserving the volume of the hippocampus, a brain structure involved in forming memories. A reduction in hippocampal volume is studied in connection with Alzheimer’s disease, but a change in MRI-measured volume does not, by itself, establish a cause or amount to a diagnosis.
Measurable absorption and benefits for memory turned out to be different outcomes. This distinction is what makes the trial useful for evaluating the claims often made about brain supplements.
A potential treatment has several steps to go through: it must enter the body, become available to the relevant tissues, change a meaningful biological process, and ultimately improve a person’s health. Success at one stage does not guarantee success at the next.
Analyzing cerebrospinal fluid helps assess the availability of a substance in the central nervous system. Memory tests answer a different question: have a person’s abilities to remember and use information changed? MRI, in turn, makes it possible to observe changes in brain structure. These measures complement one another, but they are not interchangeable.
That is why a change in a test result cannot automatically be turned into a promise of better memory. Likewise, DHA’s role in the structure of cell membranes does not mean that increasing DHA intake will necessarily improve the function of a brain that is already working normally.
The trial did not establish why the biochemical change was not accompanied by a cognitive benefit. Questions about the appropriate duration of supplementation, the stage of brain changes, and the groups that might potentially benefit remain open.
A strength of PreventE4 is its randomized allocation and comparison with placebo in a double-blind study. This design helps separate the effects of the supplement from participants’ expectations and other differences between the groups.
The main limitation was participant dropout: 225 people completed the trial, while about 38% dropped out, primarily because of the COVID-19 pandemic. This reduced the study’s ability to detect potential differences. In addition, cognitive measures were exploratory, while the primary aim concerned a biochemical marker.
The authors also acknowledge that two years may not have been long enough to detect a preventive effect in people without cognitive impairment. The full text of the study allows these limitations to be considered alongside the results. The appropriate conclusion applies to the group studied and the follow-up period: no benefit was found. This does not prove that there is no effect at any duration, dose, or stage of disease.
If you buy omega-3 supplements to improve memory or prevent dementia, PreventE4 does not confirm that they can do so. Even among people with low DHA intake at the start of the study, and despite a subsequent increase in cerebrospinal fluid DHA levels, no detectable benefit was found.
When choosing a supplement, it is useful to distinguish between two questions: “Is the substance absorbed?” and “Does the person experience a meaningful benefit?” The second question requires outcomes related to well-being, functioning, or the course of a disease. Changes in a laboratory marker alone are not enough.
The trial also did not examine whether DHA reduces the number of dementia diagnoses over many years. Its findings therefore cannot be used to promise long-term prevention, but neither do they settle the question once and for all.
No. DHA was the main component studied. Omega-3s include different fatty acids, including EPA, and supplement formulas vary. The findings of a DHA trial cannot automatically be applied to every product labeled “fish oil.”
No. PreventE4 did not compare eating fish with taking capsules. Fish contains many nutrients and is part of an overall diet. This trial cannot assess the effects of fish or a Mediterranean diet on memory.
No. This study alone is not a reason to change a prescription. It examined a specific use of DHA in people with dementia risk factors. If the supplement was prescribed for another reason, discuss its expected benefits and whether to continue taking it with your healthcare provider.
How was this article?
Share
